Teva Pharma Industries Ltd
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Teva Pharma Industries Ltd (TEVA). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| United States | $1.54B 39.5% | $1.79B 42.8% | $1.53B 38.5% | $1.70B 41.1% |
| Europe | $1.19B 30.7% | $1.30B 31.1% | $1.34B 33.7% | $1.26B 30.5% |
| Other Activities | $579.0M 14.9% | $597.0M 14.3% | $584.0M 14.7% | $627.0M 15.1% |
| International Markets | $582.0M 15.0% | $495.0M 11.9% | $524.0M 13.2% | $550.0M 13.3% |
| Corporate Segment | – | – | – | – |
| Other Segments | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|
| United States | $518.0M 33.7% | $699.0M 39.1% | $507.0M 33.1% | -$76.0M -4.5% |
| Europe | $329.0M 27.6% | $364.0M 28.0% | $401.0M 29.9% | $367.0M 29.1% |
| Other Activities | – | – | – | – |
| International Markets | $97.0M 16.7% | $74.0M 14.9% | $65.0M 12.4% | $99.0M 18.0% |
| Corporate Segment | $944.0M | $1.14B | $972.0M | $391.0M |
| Other Segments | $2.0M | -$3.0M | -$16.0M | -$16.0M |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by product line
| Segment | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|
| Sale of Goods | $3.40B 87.3% | $3.64B 87.1% | $3.91B 87.2% | $3.39B 85.1% | $3.60B 87.0% · +6.1% | $3.74B 85.1% · +2.9% |
| Distribution | $384.0M 9.9% | $377.0M 9.0% | $406.0M 9.1% | $396.0M 9.9% | $433.0M 10.5% · +12.8% | $421.0M 9.6% · +11.7% |
| Other | $76.0M 2.0% | $117.0M 2.8% | $121.0M 2.7% | $157.0M 3.9% | $70.0M 1.7% · -7.9% | $184.0M 4.2% · +57.3% |
| Licensing Arrangements | $36.0M 0.9% | $46.0M 1.1% | $46.0M 1.0% | $39.0M 1.0% | $37.0M 0.9% · +2.8% | $49.0M 1.1% · +6.5% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Operating metrics
Operating metrics are the figures a company uses to measure its own business — customer counts, stores, deliveries or the churn rate. None of them appear in the financial statements, and they often explain earlier than revenue does why revenue is moving.
| Metric | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
| US prescriptions (trailing twelve months) | 266.0M | 261.0M | 246.0M | 237.0M -10.9% | 227.0M -13.0% |
| Pending marketing authorization applications in Europe | 1,490 | 1,548 | 1,408 | 1,426 -4.3% | 1,329 -14.1% |
| Generic approvals in Europe pipeline | 273 | 496 | 89 | 267 -2.2% | 358 -27.8% |
| U.S. generic pipeline applications pending FDA approval | 128 | 123 | 112 | 101 -21.1% | 96 -22.0% |
| Share of U.S. pipeline applications with paragraph IV challenge | 74.0% | 74.0% | 81.0% | – | 79.0% +6.8% |
| Tentative approvals in U.S. generic pipeline | 69 | 68 | 65 | 59 -14.5% | 56 -17.6% |
| First-to-file products in the U.S. | 55 | 55 | 53 | 71 +29.1% | 45 -18.2% |
| AJOVY U.S. market share (anti-CGRP class) | 31.0% | 32.0% | 32.0% | 32.5% +4.8% | 32.8% +2.5% |
| Share of total U.S. generic prescriptions | 6.9% | 6.7% | 6.3% | 6.1% -11.6% | 5.8% -13.4% |
These metrics are not part of the financial statements; they sit in the narrative text of the filings. We read them out of the SEC filings using artificial intelligence and check every single figure against the original passage in the report; anything that is not found there verbatim is discarded. Source: SEC EDGAR (annual and quarterly reports, 10-K/10-Q).
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.